drugset / Trial / NCT05891119
Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis
NaSingle-groupOpen-labelBasic science
Summary
The primary objective of the study is to evaluate the pharmacokinetics (PK) of multiple cytochrome P450 (CYP450) substrates alone and in combination with rocatinlimab in participants with moderate to severe atopic dermatitis (AD).
Timeline
- Start
- 2023-06-03
- Primary completion
- 2024-08-28
- Completion
- 2025-02-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metoprolol | Other / unclassified | — | Oral |
| Subject | Midazolam | Small molecule | — | Oral |
| Subject | Omeprazole | Other / unclassified | — | Oral |
| Subject | Rocatinlimab | Monoclonal antibody | — | Subcutaneous |
| Subject | Warfarin | Small molecule | — | Oral |